Corpus luteum number and the maternal renin-angiotensin-aldosterone system as determinants of utero-placental (vascular) development: the Rotterdam Periconceptional Cohort.


Journal

Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627

Informations de publication

Date de publication:
04 Nov 2021
Historique:
received: 02 07 2021
accepted: 07 10 2021
entrez: 4 11 2021
pubmed: 5 11 2021
medline: 4 3 2022
Statut: epublish

Résumé

Pregnancies with > 1 corpus luteum (CL) display a hyperdynamic circulation and an increased risk of small-for-gestational age deliveries. Among the factors released by the CL is prorenin, the inactive precursor of renin. Since the renin-angiotensin-aldosterone system (RAAS) is involved in early hemodynamic pregnancy adaptation, we linked both CL number and first-trimester concentrations of prorenin (as an indicator of RAAS activity) and the aldosterone/renin ratio (as an indicator of angiotensin-independent aldosterone effectiveness) to non-invasive markers of utero-placental (vascular) development, measured longitudinally from the first trimester onwards. A total of 201 women, who conceived naturally or after in-vitro fertilization treatment (with 0 (n = 8), 1 (n = 143), or > 1 (n = 51) CL), were selected from the Rotterdam Periconceptional Cohort. Maternal RAAS components were determined at 11 weeks gestation. Placental volume and utero-placental vascular volume were measured from transvaginal 3D ultrasound scans at 7, 9 and 11 weeks gestation, pulsatility and resistance indices of the uterine arteries were assessed by pulsed wave Doppler ultrasounds at 7, 9, 11, 13, 22 and 32 weeks gestation. At birth placental weight was obtained using standardized procedures. Pregnancies without a CL show lower uterine artery indices throughout gestation than 1 CL and > 1 CL pregnancies, while parameters of placental development are comparable among the CL groups. After adjustment for patient- and treatment-related factors, first-trimester prorenin concentrations are positively associated with uterine artery pulsatility and resistance indices (β 0.06, 95% CI 0.01;0.12, p = 0.04 and β 0.10, 95% CI 0.01;0.20, p = 0.04, respectively), while high prorenin concentrations are negatively associated with first-trimester utero-placental vascular volume (β -0.23, 95% CI -0.44;-0.02, p = 0.04) and placental weight (β -93.8, 95%CI -160.3;-27.4, p = 0.006). In contrast, the aldosterone/renin ratio is positively associated with first-trimester placental volume (β 0.12, 95% CI 0.01;0.24, p = 0.04). The absence of a CL, resulting in low prorenin concentrations, associates with low uterine artery pulsatility and resistance, while high prorenin concentrations associate with a low utero-placental vascular volume and weight. These data support a scenario in which excess prorenin, by upregulating angiotensin II, increases uterine resistance, thereby preventing normal placental (vascular) development, and increasing the risk of small-for-gestational age deliveries. Simultaneously, high aldosterone concentrations, by ensuring volume expansion, exert the opposite.

Sections du résumé

BACKGROUND BACKGROUND
Pregnancies with > 1 corpus luteum (CL) display a hyperdynamic circulation and an increased risk of small-for-gestational age deliveries. Among the factors released by the CL is prorenin, the inactive precursor of renin. Since the renin-angiotensin-aldosterone system (RAAS) is involved in early hemodynamic pregnancy adaptation, we linked both CL number and first-trimester concentrations of prorenin (as an indicator of RAAS activity) and the aldosterone/renin ratio (as an indicator of angiotensin-independent aldosterone effectiveness) to non-invasive markers of utero-placental (vascular) development, measured longitudinally from the first trimester onwards.
METHODS METHODS
A total of 201 women, who conceived naturally or after in-vitro fertilization treatment (with 0 (n = 8), 1 (n = 143), or > 1 (n = 51) CL), were selected from the Rotterdam Periconceptional Cohort. Maternal RAAS components were determined at 11 weeks gestation. Placental volume and utero-placental vascular volume were measured from transvaginal 3D ultrasound scans at 7, 9 and 11 weeks gestation, pulsatility and resistance indices of the uterine arteries were assessed by pulsed wave Doppler ultrasounds at 7, 9, 11, 13, 22 and 32 weeks gestation. At birth placental weight was obtained using standardized procedures.
RESULTS RESULTS
Pregnancies without a CL show lower uterine artery indices throughout gestation than 1 CL and > 1 CL pregnancies, while parameters of placental development are comparable among the CL groups. After adjustment for patient- and treatment-related factors, first-trimester prorenin concentrations are positively associated with uterine artery pulsatility and resistance indices (β 0.06, 95% CI 0.01;0.12, p = 0.04 and β 0.10, 95% CI 0.01;0.20, p = 0.04, respectively), while high prorenin concentrations are negatively associated with first-trimester utero-placental vascular volume (β -0.23, 95% CI -0.44;-0.02, p = 0.04) and placental weight (β -93.8, 95%CI -160.3;-27.4, p = 0.006). In contrast, the aldosterone/renin ratio is positively associated with first-trimester placental volume (β 0.12, 95% CI 0.01;0.24, p = 0.04).
CONCLUSIONS CONCLUSIONS
The absence of a CL, resulting in low prorenin concentrations, associates with low uterine artery pulsatility and resistance, while high prorenin concentrations associate with a low utero-placental vascular volume and weight. These data support a scenario in which excess prorenin, by upregulating angiotensin II, increases uterine resistance, thereby preventing normal placental (vascular) development, and increasing the risk of small-for-gestational age deliveries. Simultaneously, high aldosterone concentrations, by ensuring volume expansion, exert the opposite.

Identifiants

pubmed: 34732224
doi: 10.1186/s12958-021-00843-9
pii: 10.1186/s12958-021-00843-9
pmc: PMC8567673
doi:

Substances chimiques

Aldosterone 4964P6T9RB

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

164

Informations de copyright

© 2021. The Author(s).

Références

Am J Obstet Gynecol. 2019 Aug;221(2):126.e1-126.e18
pubmed: 30910545
Ther Adv Cardiovasc Dis. 2008 Oct;2(5):349-62
pubmed: 19124433
Placenta. 2009 Jul;30(7):590-8
pubmed: 19476996
Mol Cell Endocrinol. 2021 Feb 15;522:111118
pubmed: 33340569
Placenta. 2009 Jun;30(6):473-82
pubmed: 19375795
Hum Reprod. 2014 Dec;29(12):2644-9
pubmed: 25336709
Circ Res. 2007 Jan 5;100(1):88-95
pubmed: 17158338
CMAJ. 2008 Mar 11;178(6):701-11
pubmed: 18332385
Aust N Z J Obstet Gynaecol. 2006 Feb;46(1):4-14
pubmed: 16441686
Eur J Epidemiol. 2013 Jan;28(1):1-19
pubmed: 23397514
Hum Reprod Update. 2006 Nov-Dec;12(6):747-55
pubmed: 16682385
Ultrasound Obstet Gynecol. 2020 Oct;56(4):603-610
pubmed: 31909549
Am J Obstet Gynecol. 2005 Aug;193(2):429-36
pubmed: 16098866
Placenta. 2018 Jan;61:96-102
pubmed: 29277277
Am J Physiol Regul Integr Comp Physiol. 2013 Jan 15;304(2):R69-72
pubmed: 23100030
Reprod Sci. 2016 Oct;23(10):1381-6
pubmed: 27071962
Hypertension. 2019 Mar;73(3):680-690
pubmed: 30636549
Hum Reprod Update. 2018 Nov 1;24(6):750-760
pubmed: 30257012
Ultrasound Obstet Gynecol. 2013 Nov;42(5):577-84
pubmed: 23996572
Clin Sci (Lond). 2014 Apr;126(8):537-44
pubmed: 24400721
J Clin Endocrinol Metab. 2003 Jan;88(1):166-73
pubmed: 12519847
Am J Obstet Gynecol. 1984 Jun 15;149(4):450-4
pubmed: 6203409
Fertil Steril. 2018 Feb;109(2):330-342.e9
pubmed: 29331236
BMC Pregnancy Childbirth. 2017 Oct 16;17(1):353
pubmed: 29037170
Int J Obes (Lond). 2020 Nov;44(11):2246-2255
pubmed: 32541920
Lancet. 2007 Mar 3;369(9563):743-749
pubmed: 17336650
J Obstet Gynaecol Br Commonw. 1973 Oct;80(10):884-7
pubmed: 4585824
J Clin Endocrinol Metab. 2020 Nov 1;105(11):
pubmed: 32853347
J Hypertens Suppl. 1992 Dec;10(7):S39-44
pubmed: 1291655
Placenta. 2021 May;108:81-90
pubmed: 33823358
Hum Reprod Update. 2018 Jan 1;24(1):35-58
pubmed: 29155965
Front Med (Lausanne). 2020 Apr 08;7:104
pubmed: 32322584
Am J Physiol. 1990 Jul;259(1 Pt 2):H197-203
pubmed: 2375406
Horm Res Paediatr. 2016;86(5):357-360
pubmed: 27685026
Obstet Gynecol. 2013 Nov;122(5):1122-1131
pubmed: 24150027
Int J Epidemiol. 2016 Apr;45(2):374-81
pubmed: 26224071
J Clin Endocrinol Metab. 1987 Aug;65(2):349-54
pubmed: 2439529
Lancet. 2019 Mar 30;393(10178):1310-1318
pubmed: 30827784
Am J Obstet Gynecol. 1985 Nov 1;153(5):514-9
pubmed: 3904454
Hum Reprod. 2020 Nov 1;35(11):2428-2438
pubmed: 33099621
J Hypertens. 2008 May;26(5):928-37
pubmed: 18398335
Hypertension. 2019 Mar;73(3):640-649
pubmed: 30636552
J Obstet Gynaecol Br Commonw. 1972 Aug;79(8):684-93
pubmed: 5070881
Endocrinology. 2011 Jan;152(1):263-71
pubmed: 21068161
Am J Obstet Gynecol. 1961 Aug;82:246-51
pubmed: 13680954
Lancet. 2010 Aug 21;376(9741):631-44
pubmed: 20598363
Obstet Gynecol. 1993 Jun;81(6):1029-33
pubmed: 8497346
Hum Reprod Update. 2013 Nov-Dec;19(6):640-55
pubmed: 23959022

Auteurs

Rosalieke E Wiegel (RE)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

Maud J H Karsten (MJH)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

Igna F Reijnders (IF)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

Lenie van Rossem (L)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

Sten P Willemsen (SP)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Department of Biostatistics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Annemarie G M G J Mulders (AGMGJ)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

Anton H J Koning (AHJ)

Department of Pathology, Clinical Bioinformatics Unit, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Eric A P Steegers (EAP)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

A H Jan Danser (AHJ)

Department of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Régine P M Steegers-Theunissen (RPM)

Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. r.steegers@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH